US Codex
Bill
Notes

H.R. 4063 — what changed

Promoting Responsible Opioid Management and Incorporating Scientific Expertise Act

From Introduced in House to Reported in House. 4 sections amended and 1 added between Introduced in House and Reported in House.

Sec. 101 Establishment of Advisory Committee to review guidelines on management of opioid therapy by Department of Veterans Affairs and Department of Defense

(a)
changed In general—Advisory Committee— Not later than one year 120 days after the date of the enactment of this Act, the Secretary of Veterans Affairs and the Secretary of Defense shall jointly update the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain to include the following:convene an advisory committee to—
(1)
changed In accordance with subsection (b), common recommended guidelines for safely prescribing opioids for the treatment conduct a thorough review of chronic, non-cancer pain in outpatient settings as compiled by the Director most recent VA/DOD Clinical Practice Guideline for Management of the Centers Opioid Therapy for Disease Control and Prevention.Chronic Pain; and
(2)
added make recommendations to the Secretaries with respect to updating the Clinical Practice Guideline.
(b)
added Matters included— In conducting the review under subsection (a)(1), the Advisory Committee shall examine whether the Clinical Practical Guideline should include the following:
(1)
renumbered was (2)(4) Enhanced guidance with respect to—
(A)
added the coadministration of an opioid and other drugs, including benzodiazepines, that may result in life-limiting drug interactions;
(A)
removed the administration of two or more drugs that may result in a life-limiting drug-to-drug interaction, including benzodiazepines;
(B)
renumbered was (2)(4)(3) the treatment of patients with current acute psychiatric instability or substance use disorder or patients at risk of suicide; and
(C)
renumbered was (2)(4)(4) the use of opioid therapy to treat mental health disorders other than opioid use disorder.
(2)
added Enhanced guidance with respect to the treatment of patients with behaviors or comorbidities, such as post-traumatic stress disorder or other psychiatric disorders, or a history of substance abuse or addiction, that requires a consultation or comanagement of opioid therapy with one or more specialists in pain management, mental health, or addictions.
(3)
added Enhanced guidance with respect to health care providers—
(A)
added conducting an effective assessment for patients beginning or continuing opioid therapy, including understanding and setting realistic goals with respect to achieving and maintaining an expected level of pain relief, improved function, or a clinically appropriate combination of both; and
(B)
added effectively assessing whether opioid therapy is achieving or maintaining the established treatment goals of the patient or whether the patient and health care provider should discuss adjusting, augmenting , or discontinuing the opioid therapy.
(4)
added Guidance that each health care provider of the Department of Veterans Affairs and the Department of Defense, before initiating opioid therapy to treat a patient as part of the comprehensive assessment conducted by the health care provider, use the Opioid Therapy Risk Report tool of the Department of Veterans Affairs (or similar monitoring tool), which shall include information from the prescription drug monitoring program of each State that includes the most recent information to date relating to the patient that accessed such program to assess the risk for adverse outcomes of opioid therapy for the patient, including the concurrent use of controlled substances such as benzodiazepines, as part of the comprehensive assessment conducted by the health care provider.
(5)
added Guidelines to govern the methodologies used by health care providers of the Department of Veterans Affairs and the Department of Defense to taper opioid therapy when adjusting or discontinuing the use of opioid therapy.
(3)
removed Enhanced guidance with respect to the treatment of patients with behaviors or comorbidities, such as post-traumatic stress disorder, psychiatric disorders, or a history of substance abuse or addiction, that requires a consultation or comanagement of opioid therapy with one or more specialists in pain management, mental health, or addictions.
(4)
removed Enhanced guidance with respect to the conduct by health care providers of an effective assessment for patients receiving opioid therapy, including patients on long-term opioid therapy, to determine—
(A)
removed whether opioid therapy is meeting the expected goals of the patient and health care provider of relieving pain, improving function, and providing patient satisfaction; and
(B)
removed whether opioid therapy should be continued.
(5)
removed Guidance that each health care provider of the Department of Veterans Affairs and the Department of Defense, before initiating opioid therapy to treat a patient as part of the comprehensive assessment conducted by the health care provider, use the Opioid Therapy Risk Report tool of the Department of Veterans Affairs (or successor tool), which shall include the ability to access the most recent patient information from the prescription drug monitoring program of each State that has such a program to assess the risk for adverse outcomes of opioid therapy for the patient, including with respect to the concurrent use of controlled substances, including benzodiazepines.
(6)
removed Guidelines to govern the methodologies used by health care providers of the Department of Veterans Affairs and the Department of Defense to safely titrate and taper opioid therapy when adjusting or discriminating the use of opioid therapy, including with respect to—
(A)
removed prescription of the lowest effective dose based on patient need;
(B)
removed use of opioid only for a limited period of time; and
(C)
removed augmentation of opioid therapy with other pain management therapies and modalities.
(6)
renumbered was (2)(9) Guidelines with respect to appropriate case management for patients receiving opioid therapy who transition between inpatient and outpatient health care settings, which may include the use of care transition plans.
(7)
added Guidelines with respect to appropriate case management for patients receiving opioid therapy who transition from receiving care during active duty to post-military health care networks.
(8)
removed Guidelines with respect to appropriate transfer of case management responsibility for patients receiving opioid therapy who transition from receiving care furnished by the Secretary of Defense to receiving care furnished by other health care providers after the patient has been discharged or separated from the Armed Forces.
(8)
renumbered was (2)(11) Enhanced standards with respect to the use of routine and random urine drug tests for all patients before and during opioid therapy to help prevent substance abuse, dependence, and diversion, including—
(A)
renumbered was (2)(11)(2) that such tests occur not less frequently than once each year; and
(B)
added that health care providers appropriately order, interpret and respond to the results from such tests to tailor pain therapy, safeguards, and risk management strategies to each patient.
(B)
removed that health care providers appropriately interpret and respond to the results from such tests to tailor pain therapy, safeguards, and risk management strategies to each patient.
(9)
renumbered was (2)(12) Guidance that health care providers discuss with patients, before initiating opioid therapy, options for pain management therapies without the use of opioids and options to augment opioid therapy with other clinical and complementary and integrative health services to minimize opioid dependence.
(10)
added Guidance for health care providers with respect to evidence-based non-opioid treatments within the Department of Veterans Affairs and the Department of Defense, including medical devices and other therapies approved or cleared by the Food and Drug Administration for the treatment of chronic pain as an alternative to or to augment opioid therapy.
(b)
removed Treatment of certain guidelines developed after deadline— If the Director of the Centers for Disease Control and Prevention issues the guidelines described in paragraph (1) of subsection (a) after the date on which the Secretary of Veterans Affairs and the Secretary of Defense jointly update the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain pursuant to such subsection, the Secretaries shall jointly modify the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain to incorporate such guidelines of the Director.
(c)
changed Consultation before update—Consultation— Before updating In carrying out the guideline review under paragraph (1) of subsection (a), the Secretary of Veterans Affairs and before making the Secretary recommendations under paragraph (2) of Defense such subsection, the Advisory Committee shall jointly consult with the Pain VA/DOD Management Working Group of the Department of Veterans Affairs–Department of Defense Joint Executive Committee established by section 320 of title 38, United States Code.Opioid Therapy for Chronic Pain Working Group.
(d)
added Submission— Not later than one year after the date of the enactment of this Act, the Advisory Committee shall submit to the Secretaries the review and recommendations described in subsection (a)(1).
(e)
added Application of Federal Advisory Committee Act— The provisions of the Federal Advisory Committee Act (5 U.S.C. App.) shall apply to the Advisory Committee.
(f)
renumbered was (5) Definitions— In this section:
(1)
added The term “Advisory Committee” means the advisory committee established under subsection (a).
(2)
added The term “Clinical Practice Guideline” means the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain.
(3)
added The term “controlled substance” has the meaning given that term in section 102 of the Controlled Substances Act (21 U.S.C. 802).
(4)
added The term “State” means each of the several States, territories, and possessions of the United States, the District of Columbia, and the Commonwealth of Puerto Rico.
(1)
removed The term controlled substance has the meaning given that term in section 102 of the Controlled Substances Act (21 U.S.C. 802).
(2)
removed The term State means each of the several States, territories, and possessions of the United States, the District of Columbia, and the Commonwealth of Puerto Rico.

Sec. 102 Improvement of opioid safety measures by Department of Veterans Affairs

(a)
Expansion of opioid safety initiative— Not later than 180 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall expand the Opioid Safety Initiative of the Department of Veterans Affairs to include all medical facilities of the Department.
(b)
Pain management education and training—
(1)
In general— In carrying out the Opioid Safety Initiative of the Department, the Secretary shall require all employees of the Department responsible for prescribing opioids to receive education and training described in paragraph (2).
(2)
Education and training— Education and training described in this paragraph is education and training on pain management and safe opioid prescribing practices for purposes of safely and effectively managing patients with chronic pain, including education and training on the following:
(A)
The implementation of and full compliance with the VA/DOD Clinical Practice Guideline for Management of Opioid Therapy for Chronic Pain, including any update to such guideline.
(B)
changed The use of evidence-based pain management therapies, including cognitive-behavioral therapy, non-opioid alternatives, and non-drug methods and procedures to managing pain and related health conditions including medical devices approved or cleared by the Food and Drug Administration for the treatment of patients with chronic pain and complementary alternative medicines.
(C)
Screening and identification of patients with substance use disorder, including drug-seeking behavior, before prescribing opioids, assessment of risk potential for patients developing an addiction, and referral of patients to appropriate addiction treatment professionals if addiction is identified or strongly suspected.
(D)
Communication with patients on the potential harm associated with the use of opioids and other controlled substances, including the need to safely store and dispose of supplies relating to the use of opioids and other controlled substances.
(E)
Such other education and training as the Secretary considers appropriate to ensure that veterans receive safe and high-quality pain management care from the Department.
(3)
Use of existing program— In providing education and training described in paragraph (2), the Secretary shall use the Interdisciplinary Chronic Pain Management Training Team Program of the Department (or success program).
(c)
Pain management teams—
(1)
In general— In carrying out the Opioid Safety Initiative of the Department, the director of each medical facility of the Department shall identify and designate a pain management team of health care professionals, which may include board certified pain medicine specialists, responsible for coordinating and overseeing pain management therapy at such facility for patients experiencing acute and chronic pain that is non-cancer related.
(2)
Establishment of protocols—
(A)
In general— In consultation with the Directors of each Veterans Integrated Service Network, the Secretary shall establish standard protocols for the designation of pain management teams at each medical facility within the Department.
(B)
Consultation on prescription of opioids— Each protocol established under subparagraph (A) shall ensure that any health care provider without expertise in prescribing analgesics or who has not completed the education and training under subsection (b), including a mental health care provider, does not prescribe opioids to a patient unless that health care provider—
(i)
consults with a health care provider with pain management expertise or who is on the pain management team of the medical facility; and
(ii)
refers the patient to the pain management team for any subsequent prescriptions and related therapy.
(3)
Report—
(A)
In general— Not later than one year after the date of enactment of this Act, the director of each medical facility of the Department shall submit to the Under Secretary for Health and the director of the Veterans Integrated Service Network in which the medical facility is located a report identifying the health care professionals that have been designated as members of the pain management team at the medical facility pursuant to paragraph (1).
(B)
Elements— Each report submitted under subparagraph (A) with respect to a medical facility of the Department shall include—
(i)
changed a certification as to whether all members of the pain management team at the medical facility have completed the education and training required under subsection (b); and(b);
(ii)
changed a plan for the management and referral of patients to such pain management team if health care providers without expertise in prescribing analgesics prescribe opioid medications to treat acute and chronic pain that is non-cancer related.related; and
(iii)
added a certification as to whether the medical facility—
(I)
added fully complies with the stepped-care model of pain management and other pain management policies contained in Directive 2009-053 of the Veterans Health Administration, or successor directive; or
(II)
added does not fully comply with such stepped-care model of pain management and other pain management policies but is carrying out a corrective plan of action to ensure such full compliance.
(d)
Tracking and monitoring of opioid use—
(1)
Prescription drug monitoring programs of states— In carrying out the Opioid Safety Initiative and the Opioid Therapy Risk Report tool of the Department, the Secretary shall—
(A)
ensure access by health care providers of the Department to information on controlled substances, including opioids and benzodiazepines, prescribed to veterans who receive care outside the Department through the prescription drug monitoring program of each State with such a program, including by seeking to enter into memoranda of understanding with States to allow shared access of such information between States and the Department;
(B)
include such information in the Opioid Therapy Risk Report; and
(C)
require health care providers of the Department to submit to the prescription drug monitoring program of each State information on prescriptions of controlled substances received by veterans in that State under the laws administered by the Secretary.
(2)
Report on tracking of data on opioid use— Not later than 18 months after the date of the enactment of this Act, the Secretary shall submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report on the feasibility and advisability of improving the Opioid Therapy Risk Report tool of the Department to allow for more advanced real-time tracking of and access to data on—
(A)
the key clinical indicators with respect to the totality of opioid use by veterans;
(B)
concurrent prescribing by health care providers of the Department of opioids in different health care settings, including data on concurrent prescribing of opioids to treat mental health disorders other than opioid use disorder; and
(C)
mail-order prescriptions of opioid prescribed to veterans under the laws administered by the Secretary.
(e)
Availability of opioid receptor antagonists—
(1)
Increased availability and use—
(A)
In general— The Secretary shall maximize the availability of opioid receptor antagonists approved by the Food and Drug Administration, including naloxone, to veterans.
(B)
Availability, training, and distributing— In carrying out subparagraph (A), not later than 90 days after the date of the enactment of this Act, the Secretary shall—
(i)
equip each pharmacy of the Department with opioid receptor antagonists approved by the Food and Drug Administration to be dispensed to outpatients as needed; and
(ii)
expand the Overdose Education and Naloxone Distribution program of the Department to ensure that all veterans in receipt of health care under laws administered by the Secretary who are at risk of opioid overdose may access such opioid receptor antagonists and training on the proper administration of such opioid receptor antagonists.
(C)
Veterans who are at risk— For purposes of subparagraph (B), veterans who are at risk of opioid overdose include—
(i)
veterans receiving long-term opioid therapy;
(ii)
veterans receiving opioid therapy who have a history of substance use disorder or prior instances of overdose; and
(iii)
veterans who are at risk as determined by a health care provider who is treating the veteran.
(2)
Report— Not later than 120 days after the date of the enactment of this Act, the Secretary shall submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report on carrying out paragraph (1), including an assessment of any remaining steps to be carried out by the Secretary to carry out such paragraph.
(f)
Inclusion of certain information and capabilities in opioid therapy risk report tool of the Department—
(1)
Information— The Secretary shall include in the Opioid Therapy Risk Report tool of the Department—
(A)
information on the most recent time the tool was accessed by a health care provider of the Department with respect to each veteran; and
(B)
information on the results of the most recent urine drug test for each veteran.
(2)
Capabilities— The Secretary shall include in the Opioid Therapy Risk Report tool the ability of the health care providers of the Department to determine whether a health care provider of the Department prescribed opioids to a veteran without checking the information in the tool with respect to the veteran.
(g)
Notifications of risk in computerized health record— The Secretary shall modify the computerized patient record system of the Department to ensure that any health care provider that accesses the record of a veteran, regardless of the reason the veteran seeks care from the health care provider, will be immediately notified whether the veteran—
(1)
is receiving opioid therapy and has a history of substance use disorder or prior instances of overdose;
(2)
has a history of opioid abuse; or
(3)
is at risk of becoming an opioid abuser as determined by a health care provider who is treating the veteran.
(h)
Definitions— In this section:
(1)
The term controlled substance has the meaning given that term in section 102 of the Controlled Substances Act (21 U.S.C. 802).
(2)
The term State means each of the several States, territories, and possessions of the United States, the District of Columbia, and the Commonwealth of Puerto Rico.

Sec. 105 Mandatory disclosure of certain veteran information to State controlled substance monitoring programs

added

added Section 5701(l) of title 38, United States Code, is amended by striking “may” and inserting “shall”.

Sec. 301 Expansion of research and education on and delivery of complementary and integrative health to veterans

(a)
Establishment— There is established a commission to be known as the “Creating Options for Veterans’ Expedited Recovery” or the “COVER Commission” (in this Act referred to as the “Commission”). The Commission shall examine the evidence-based therapy treatment model used by the Secretary of Veterans Affairs for treating mental health conditions of veterans and the potential benefits of incorporating complementary alternative treatments available in non-Department facilities (as defined in section 1701 of title 38, United States Code).
(b)
Duties— The Commission shall perform the following duties:
(1)
Examine the efficacy of the evidence-based therapy model used by the Secretary for treating mental health illnesses of veterans and identify areas to improve wellness-based outcomes.
(2)
Conduct a patient-centered survey within each of the Veterans Integrated Service Networks to examine—
(A)
the experience of veterans with the Department of Veterans Affairs when seeking medical assistance for mental health issues through the health care system of the Department;
(B)
the experience of veterans with non-Department facilities and health professionals for treating mental health issues;
(C)
the preference of veterans regarding available treatment for mental health issues and which methods the veterans believe to be most effective;
(D)
the experience, if any, of veterans with respect to the complementary alternative treatment therapies described in paragraph (3);
(E)
the prevalence of prescribing prescription medication among veterans seeking treatment through the health care system of the Department as remedies for addressing mental health issues; and
(F)
the outreach efforts of the Secretary regarding the availability of benefits and treatments for veterans for addressing mental health issues, including by identifying ways to reduce barriers to gaps in such benefits and treatments.
(3)
Examine available research on complementary alternative treatment therapies for mental health issues and identify what benefits could be made with the inclusion of such treatments for veterans, including with respect to—
(A)
music therapy;
(B)
equine therapy;
(C)
training and caring for service dogs;
(D)
yoga therapy;
(E)
acupuncture therapy;
(F)
meditation therapy;
(G)
outdoor sports therapy;
(H)
hyperbaric oxygen therapy;
(I)
accelerated resolution therapy;
(J)
art therapy;
(K)
magnetic resonance therapy; and
(L)
other therapies the Commission determines appropriate.
(4)
Study the sufficiency of the resources of the Department to ensure the delivery of quality health care for mental health issues among veterans seeking treatment within the Department.
(5)
Study the current treatments and resources available within the Department and assess—
(A)
the effectiveness of such treatments and resources in decreasing the number of suicides per day by veterans;
(B)
the number of veterans who have been diagnosed with mental health issues;
(C)
the percentage of veterans using the resources of the Department who have been diagnosed with mental health issues;
(D)
the percentage of veterans who have completed counseling sessions offered by the Department; and
(E)
the efforts of the Department to expand complementary alternative treatments viable to the recovery of veterans with mental health issues as determined by the Secretary to improve the effectiveness of treatments offered with the Department.
(c)
Membership—
(1)
In general— The Commission shall be composed of 10 members, appointed as follows:
(A)
Two members appointed by the Speaker of the House of Representatives, at least one of whom shall be a veteran.
(B)
Two members appointed by the Minority Leader of the House of Representatives, at least one of whom shall be a veteran.
(C)
Two members appointed by the Majority Leader of the Senate, at least one of whom shall be a veteran.
(D)
Two members appointed by the Minority Leader of the Senate, at least one of whom shall be a veteran.
(E)
Two members appointed by the President, at least one of whom shall be a veteran.
(2)
Qualifications— Members of the Commission shall be—
(A)
individuals who are of recognized standing and distinction within the medical community with a background in treating mental health;
(B)
individuals with experience working with the military and veteran population; and
(C)
individuals who do not have a financial interest in any of the complementary alternative treatments reviewed by the Commission.
(3)
Chairman— The President shall designate a member of the Commission to be the Chairman.
(4)
Period of appointment— Members of the Commission shall be appointed for the life of the Commission.
(5)
Vacancy— A vacancy in the Commission shall be filled in the manner in which the original appointment was made.
(6)
Appointment deadline— The appointment of members of the Commission in this section shall be made not later than 90 days after the date of the enactment of this Act.
(d)
Powers of commission—
(1)
Meetings—
(A)
Initial meeting— The Commission shall hold its first meeting not later than 30 days after a majority of members are appointed to the Commission.
(B)
Meeting— The Commission shall regularly meet at the call of the Chairman. Such meetings may be carried out through the use of telephonic or other appropriate telecommunication technology if the Commission determines that such technology will allow the members to communicate simultaneously.
(2)
Hearings— The Commission may hold such hearings, sit and act at such times and places, take such testimony, and receive evidence as the Commission considers advisable to carry out the responsibilities of the Commission.
(3)
Information from federal agencies— The Commission may secure directly from any department or agency of the Federal Government such information as the Commission considers necessary to carry out the duties of the Commission.
(4)
Information from nongovernmental organizations— In carrying out its duties, the Commission may seek guidance through consultation with foundations, veteran service organizations, nonprofit groups, faith-based organizations, private and public institutions of higher education, and other organizations as the Commission determines appropriate.
(5)
Commission records— The Commission shall keep an accurate and complete record of the actions and meeting of the Commission. Such record shall be made available for public inspection and the Comptroller General of the United States may audit and examine such record.
(6)
Personnel records— The Commission shall keep an accurate and complete record of the actions and meetings of the Commission. Such record shall be made available for public inspection and the Comptroller General of the United States may audit and examine such records.
(7)
Compensation of members; travel expenses— Each member shall serve without pay but shall receive travel expenses to perform the duties of the Commission, including per diem in lieu of substances, at rates authorized under subchapter I of chapter 57 of title 5, United States Code.
(8)
Staff— The Chairman, in accordance with rules agreed upon the Commission, may appoint fix the compensation of a staff director and such other personnel as may be necessary to enable the Commission to carry out its functions, without regard to the provisions of title 5, United States Code, governing appointments in the competitive service, without regard to the provision of chapter 51 and subchapter III of chapter 53 of such title relating to classification and General Schedule pay rates, except that no rate of pay fixed under this paragraph may exceed the equivalent of that payable for a position at a level IV of the Executive Schedule under section 5316 of title 5, United States Code.
(9)
Personnel as federal employees—
(A)
In general— The executive director and any personnel of the Commission are employees under section 2105 of title 5, United States Code, for purpose of chapters 63, 81, 83, 84, 85, 87, 89, and 90 of such title.
(B)
Members of the commission— Subparagraph (A) shall not be construed to apply to members of the Commission.
(10)
Contracting— The Commission may, to such extent and in such amounts as are provided in appropriations Acts, enter into contracts to enable the Commission to discharge the duties of the Commission under this Act.
(11)
Expert and consultant service— The Commission may procure the services of experts and consultants in accordance with section 3109 or title 5, United States Code, at rates not to exceed the daily rate paid to a person occupying a position at level IV of the Executive Schedule under section 3109 of title 5, United States Code.
(12)
Postal service— The Commission may use the United States mails in the same manner and under the same conditions as departments and agencies of the United States.
(13)
Physical facilities and equipment— Upon the request of the Commission, the Administrator of General Services shall provide to the Commission, on a reimbursable basis, the administrative support services necessary for the Commission to carry out its responsibilities under this Act. These administrative services may include human resource management, budget, leasing accounting, and payroll services.
(e)
Report—
(1)
Interim reports—
(A)
In general— Not later than 60 days after the date on which the Commission first meets, and each 30-day period thereafter ending on the date on which the Commission submits the final report under paragraph (2), the Commission shall submit to the Committees on Veterans’ Affairs of the House of Representatives and the Senate and the President a report detailing the level of cooperation the Secretary of Veterans Affairs (and the heads of other departments or agencies of the Federal Government) has provided to the Commission.
(B)
Other reports— In carrying out its duties, at times that the Commission determines appropriate, the Commission shall submit to the Committee on Veterans’ Affairs of the House of Representatives and the Senate and any other appropriate entities an interim report with respect to the findings identified by the Commission.
(2)
Final report— Not later than 18 months after the first meeting of the Commission, the Commission shall submit to the Committee on Veterans’ Affairs of the House of Representatives and the Senate, the President, and the Secretary of Veterans Affairs a final report on the findings of the Commission. Such report shall include the following:
(A)
Recommendations to implement in a feasible, timely, and cost efficient manner the solutions and remedies identified within the findings of the Commission pursuant to subsection (b).
(B)
An analysis of the evidence-based therapy model used by the Secretary of Veterans Affairs for treating veterans with mental health care issues, and an examination of the prevalence and efficacy of prescription drugs as a means for treatment.
(C)
The findings of the patient-centered survey conducted within each of the Veterans Integrated Service Networks pursuant to subsection (b)(2).
(D)
An examination of complementary alternative treatments described in subsection (b)(3) and the potential benefits of incorporating such treatments in the therapy models used by the Secretary for treating veterans with mental health issues.
(3)
Plan— Not later than 90 days after the date on which the Commission submits the final report under paragraph (2), the Secretary of Veterans Affairs shall submit to the Committee on Veterans’ Affairs of the House of Representatives and the Senate a report on the following:
(A)
An action plan for implementing the recommendations established by the Commission on such solutions and remedies for improving wellness-based outcomes for veterans with mental health care issues.
(B)
changed A feasible timeframe on when the complementary alternative treatments described in subsection (b)(3) can be implemented Departmentwide.Department-wide.
(C)
With respect to each recommendation established by the Commission, including any complementary alternative treatment, that the Secretary determines is not appropriate or feasible to implement, a justification for such determination and an alternative solution to improve the efficacy of the therapy models used by the Secretary for treating veterans with mental health issues.
(f)
Termination of commission— The Commission shall terminate 30 days after the Commission submits the final report under subsection (e)(2).

Sec. 403 Report on compliance by Department of Veterans Affairs with reviews of health care providers leaving the Department or transferring to other facilities

changed Not later than two years 180 days after the date of the enactment of this Act, the Secretary of Veterans Affairs shall submit to the Committee on Veterans’ Affairs of the Senate and the Committee on Veterans’ Affairs of the House of Representatives a report on the compliance by the Department of Veterans Affairs with the policy of the Department—

(1)
to conduct a review of each health care provider of the Department who transfers to another medical facility of the Department, retires, or is terminated to determine whether there are any concerns, complaints, or allegations of violations relating to the medical practice of the health care provider; and
(2)
to take appropriate action with respect to any such concern, complaint, or allegation.